Insider Buying: Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Purchases 26,500 Shares of Stock

Share on StockTwits

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Director Albert Cha acquired 26,500 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was purchased at an average price of $16.83 per share, for a total transaction of $445,995.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Albert Cha also recently made the following trade(s):

  • On Monday, July 29th, Albert Cha acquired 56,367 shares of Kalvista Pharmaceuticals stock. The stock was purchased at an average price of $16.99 per share, for a total transaction of $957,675.33.
  • On Wednesday, July 17th, Albert Cha acquired 1,280 shares of Kalvista Pharmaceuticals stock. The stock was purchased at an average price of $16.96 per share, for a total transaction of $21,708.80.
  • On Friday, July 19th, Albert Cha acquired 61,280 shares of Kalvista Pharmaceuticals stock. The stock was purchased at an average price of $17.79 per share, for a total transaction of $1,090,171.20.

Shares of NASDAQ KALV opened at $16.11 on Friday. Kalvista Pharmaceuticals Inc has a 1 year low of $12.35 and a 1 year high of $34.92. The company’s 50-day moving average is $17.69 and its 200 day moving average is $21.93. The stock has a market capitalization of $282.59 million, a P/E ratio of -11.67 and a beta of 2.10.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Monday, July 15th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.07). Kalvista Pharmaceuticals had a negative return on equity of 24.57% and a negative net margin of 127.20%. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.64 million. On average, equities analysts anticipate that Kalvista Pharmaceuticals Inc will post -2.67 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new stake in Kalvista Pharmaceuticals during the second quarter worth about $42,000. Strs Ohio bought a new stake in Kalvista Pharmaceuticals during the second quarter worth about $68,000. Bank of Montreal Can boosted its stake in Kalvista Pharmaceuticals by 28.5% during the first quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock worth $166,000 after acquiring an additional 1,292 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in Kalvista Pharmaceuticals during the first quarter worth about $175,000. Finally, Virtus ETF Advisers LLC bought a new stake in Kalvista Pharmaceuticals during the second quarter worth about $297,000. 79.68% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have issued reports on KALV shares. Zacks Investment Research cut shares of Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, July 17th. ValuEngine cut shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Leerink Swann assumed coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, July 29th. They set an “outperform” rating and a $31.00 price target on the stock. BidaskClub cut shares of Kalvista Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Finally, Roth Capital reiterated a “buy” rating on shares of Kalvista Pharmaceuticals in a research report on Tuesday, May 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $29.86.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: What is the Coverage Ratio?

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.